142 related articles for article (PubMed ID: 26097419)
21. Preparation and preliminary biological evaluation of 177Lu-labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints.
Chakraborty S; Das T; Banerjee S; Sarma HD; Venkatesh M
Nucl Med Commun; 2006 Aug; 27(8):661-8. PubMed ID: 16829766
[TBL] [Abstract][Full Text] [Related]
22. 177Lu-EDTMP: a potential therapeutic bone agent.
Ando A; Ando I; Tonami N; Kinuya S; Kazuma K; Kataiwa A; Nakagawa M; Fujita N
Nucl Med Commun; 1998 Jun; 19(6):587-91. PubMed ID: 10234664
[TBL] [Abstract][Full Text] [Related]
23. Preparation and preliminary studies on 177Lu-labeled hydroxyapatite particles for possible use in the therapy of liver cancer.
Chakraborty S; Das T; Sarma HD; Venkatesh M; Banerjee S
Nucl Med Biol; 2008 Jul; 35(5):589-97. PubMed ID: 18589303
[TBL] [Abstract][Full Text] [Related]
24. Production, biodistribution assessment and dosimetric evaluation of (177)Lu-TTHMP as an agent for bone pain palliation.
Zolghadri S; Yousefnia H; Jalilian AR; Ghannadi-Maragheh M
Asia Ocean J Nucl Med Biol; 2015; 3(1):35-42. PubMed ID: 27408879
[TBL] [Abstract][Full Text] [Related]
25. Radiosynovectomy of Painful Synovitis of Knee Joints Due to Rheumatoid Arthritis by Intra-Articular Administration of (177)Lu-Labeled Hydroxyapatite Particulates: First Human Study and Initial Indian Experience.
Shinto AS; Kamaleshwaran KK; Chakraborty S; Vyshakh K; Thirumalaisamy SG; Karthik S; Nagaprabhu VN; Vimalnath KV; Das T; Banerjee S
World J Nucl Med; 2015; 14(2):81-8. PubMed ID: 26097417
[TBL] [Abstract][Full Text] [Related]
26. Ethylene diamine tetramethylene phosphonic acid labeled with various β(-)-emitting radiometals: labeling optimization and animal biodistribution.
Sohaib M; Ahmad M; Jehangir M; Perveen A
Cancer Biother Radiopharm; 2011 Apr; 26(2):159-64. PubMed ID: 21510750
[TBL] [Abstract][Full Text] [Related]
27. Comparative Therapeutic Efficacy of
Sharma S; Singh B; Koul A; Mittal BR
Front Med (Lausanne); 2017; 4():46. PubMed ID: 28507988
[TBL] [Abstract][Full Text] [Related]
28. (177)Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment.
Bergmann R; Meckel M; Kubíček V; Pietzsch J; Steinbach J; Hermann P; Rösch F
EJNMMI Res; 2016 Dec; 6(1):5. PubMed ID: 26780082
[TBL] [Abstract][Full Text] [Related]
29. Novel developed HPLC analyses of [
Eryilmaz K; Bakar HE; Kilbas B
J Labelled Comp Radiopharm; 2022 Jun; 65(7):178-186. PubMed ID: 35466456
[TBL] [Abstract][Full Text] [Related]
30. Radiolabeling, quality control, biodistribution, and imaging studies of
Xu Q; Zhang S; Zhao Y; Feng Y; Liu L; Cai L; Zhang W; Huang Z; Wei H; Zhuo L; Chen Y
J Labelled Comp Radiopharm; 2019 Jan; 62(1):43-51. PubMed ID: 30426535
[TBL] [Abstract][Full Text] [Related]
31. Formulation and
Mercanoglu G; Alcın G; Ozturkmen Y; Cermik T
Curr Radiopharm; 2024; 17(1):68-76. PubMed ID: 37937551
[TBL] [Abstract][Full Text] [Related]
32. Radiosynovectomy of the elbow joint synovitis in rheumatoid arthritis treated with Lutetium - 177 labeled hydroxylapatite (Lu-177 HA) particulates; first case report and image of Lu -177 HA in the elbow joint.
Kamaleshwaran KK; Rajamani V; Thirumalaisamy SG; Chakraborty S; Kalarikal R; Mohanan V; Shinto AS
Indian J Nucl Med; 2014 Oct; 29(4):270-2. PubMed ID: 25400373
[TBL] [Abstract][Full Text] [Related]
33. Production, quality control, and determination of human absorbed dose of no carrier added
Salek N; Mehrabi M; Shirvani Arani S; Bahrami Samani A; Erfani M; Vosoghi S; Ghannadi Maragheh M; Shamsaei M
J Labelled Comp Radiopharm; 2017 Jan; 60(1):20-29. PubMed ID: 27862203
[TBL] [Abstract][Full Text] [Related]
34. Studies on the development of 99mTc-labeled biphosphonate alginate beads.
Vishwakarma M; Bandopadhyaya GP
Hell J Nucl Med; 2010; 13(3):224-8. PubMed ID: 21193874
[TBL] [Abstract][Full Text] [Related]
35. Preparation and biological evaluation of 188Re-ethylenediamine-N,N,N',N'-tetrakis(methylene phosphonic acid) as a potential agent for bone pain palliation.
Oh SJ; Won KS; Moon DH; Cheon JH; Ha HJ; Jeong JM; Lee HK
Nucl Med Commun; 2002 Jan; 23(1):75-81. PubMed ID: 11748441
[TBL] [Abstract][Full Text] [Related]
36. Estimation of Whole Body Radiation Exposure to Nuclear Medicine Personnel During Synthesis of
Arora G; Mishra R; Kumar P; Yadav M; Ballal S; Bal C; Damle NA
Indian J Nucl Med; 2017; 32(2):89-92. PubMed ID: 28533634
[TBL] [Abstract][Full Text] [Related]
37. Production, quality control, biodistribution assessment and preliminary dose evaluation of (177)Lu-PDTMP as a possible bone palliative agent.
Yousefnia H; Jalilian AR; Zolghadri S; Ghannadi-Maragheh M
Nucl Med Commun; 2014 Jan; 35(1):99-107. PubMed ID: 24162837
[TBL] [Abstract][Full Text] [Related]
38. Radiolabeling, quality control, and biological characterization of
Akbar MU; Bokhari TH; Khalid M; Ahmad MR; Roohi S; Hina S; Mehmood S; Sohaib M; Jabbar T
Chem Biol Drug Des; 2017 Sep; 90(3):425-431. PubMed ID: 28152272
[TBL] [Abstract][Full Text] [Related]
39. 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis.
Chakraborty S; Das T; Banerjee S; Balogh L; Chaudhari PR; Sarma HD; Polyák A; Máthé D; Venkatesh M; Janoki G; Pillai MR
Cancer Biother Radiopharm; 2008 Apr; 23(2):202-13. PubMed ID: 18454689
[TBL] [Abstract][Full Text] [Related]
40. Production, quality control, and bio-distribution studies of (159)Gd-EDTMP as a palliative agent for bone pain.
Arani SS; Ghasemi S; Samani AB; Zafarghandi MS
Electron Physician; 2015; 7(1):977-84. PubMed ID: 26052408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
